Literature DB >> 2367159

Gamma-globulin treatment of recurrent acute otitis media in children.

F Jørgensen1, B Andersson, L A Hanson, O Nylén, C S Edén.   

Abstract

This study examined the hypothesis that children prone to acute otitis media have a reduced concentration of circulating antibodies of the IgG2 subclass and that this defect can be compensated for by gamma-globulin treatment. Infants and children below 18 months of age with at least three episodes of acute otitis media were randomized to intramuscular gamma-globulin or no treatment and were followed for 6 months. We could demonstrate neither reduced IgG2 nor specific anti-polysaccharide antibody activity in the otitis-prone children. In contrast they had higher concentrations of IgG2 and antibodies to phosphorylcholine than did age-matched controls. There was neither a relationship between the IgG2 concentration and the number of otitis episodes prior to enrollment nor a reduction in otitis frequency in the gamma-globulin-treated group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2367159     DOI: 10.1097/00006454-199006000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  3 in total

1.  Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Vaccine       Date:  2010-12-01       Impact factor: 3.641

2.  Successful intravenous immunoglobulin therapy for recurrent pneumococcal otitis media in young children.

Authors:  A Ishizaka; Y Sakiyama; M Otsu; K Ozutsumi; S Matsumoto
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

Review 3.  Immunologic screening of children with recurrent otitis media.

Authors:  Selma P Wiertsema; Reinier H Veenhoven; Elisabeth A M Sanders; Ger T Rijkers
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.